Skip to main content
Evidence: A✓ FDA-approvedSexual HealthFertility & HPG Axis

Gonadorelin: Benefits, Dosage & FDA Status

Gonadorelin (GnRH)

Synthetic GnRH used clinically to stimulate LH/FSH release. In testosterone replacement therapy, used pulsatile to preserve testicular size and fertility instead of hCG.

FDA Status

FDA-approved (Factrel) historically for diagnostic GnRH stimulation; off-label use in TRT to preserve testicular function

Typical Dose

100–500 mcg every 1–3 days (subcutaneous, pulsatile)

Evidence Grade

AStrong RCT or FDA-approved evidence

Half-Life

~5 minutes

Routes of Administration

subcutaneous

First Synthesized

1971

Clinics Indexed

156 providers have offered Gonadorelin in our tracked directory.

Mechanism of Action

Decapeptide identical to endogenous GnRH; pulsatile dosing drives LH/FSH release without HPG-axis desensitization.

Key Reported Benefits

Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade A indicates strong rct or fda-approved evidence.

Reported Side Effects

  • Injection-site reactions
  • Headache (rare)

Contraindications

  • Hormone-sensitive cancers
  • Pregnancy

Regulatory & Safety Context

FDA status: FDA-approved (Factrel) historically for diagnostic GnRH stimulation; off-label use in TRT to preserve testicular function

This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.

See state-by-state legality: US peptide legality by state →

References

Selected primary literature on Gonadorelin. Full PubMed records linked. Additional citations are available on request.

  1. PubMed PMID 1856392

Last reviewed: 2026-04-30

← Back to all peptides